SRC and chronic myelogenous leukemia, BCR-ABL1 positive: A novel drug named Dasatinib (BMS-354825, SPRYCEL®; Bristol-Myers Squibb) is a highly potent ATP-competitive orally active dual Src/Abl kinase inhibitor with anti-proliferative activity against solid tumors and CML (chronic myeloid leukaemia) cell lines.